<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tarsus Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc</link>
<description>Latest news and press releases for Tarsus Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tarsus-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c75478dffbe2df11b692.webp</url>
<title>Tarsus Pharmaceuticals Inc</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc</link>
</image>
<item>
<title>Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-to-report-first-quarter-2026-financial-results-on-wednesday-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-to-report-first-quarter-2026-financial-results-on-wednesday-may-6-2026</guid>
<pubDate>Wed, 29 Apr 2026 20:30:00 GMT</pubDate>
<description>IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsu</description>
</item>
<item>
<title>Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-doses-first-participant-in-calliope-a-phase-2-clinical-trial-of-tp-05-lotilaner-a-novel-investigational-oral-tablet-for-the-potential-prevention-of-lyme-disease</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-doses-first-participant-in-calliope-a-phase-2-clinical-trial-of-tp-05-lotilaner-a-novel-investigational-oral-tablet-for-the-potential-prevention-of-lyme-disease</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026</description>
</item>
<item>
<title>TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tp-03-lotilaner-ophthalmic-solution-025percent-now-approved-in-china-for-the-treatment-of-demodex-blepharitis-triggering-a-dollar15m-milestone-payment-to-tarsus</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tp-03-lotilaner-ophthalmic-solution-025percent-now-approved-in-china-for-the-treatment-of-demodex-blepharitis-triggering-a-dollar15m-milestone-payment-to-tarsus</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus</description>
</item>
<item>
<title>Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-achievements</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-achievements</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026</description>
</item>
<item>
<title>Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-pharmaceuticals-appoints-renowned-biopharmaceutical-leader-and-former-allergan-ceo-david-pyott-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-pharmaceuticals-appoints-renowned-biopharmaceutical-leader-and-former-allergan-ceo-david-pyott-to-its-board-of-directors</guid>
<pubDate>Wed, 18 Feb 2026 13:30:00 GMT</pubDate>
<description>David E. I. Pyott David E. I. Pyott, former Chairman and CEO of Allergan, Inc., was appointed to Tarsus Pharmaceuticals' Board of Directors. IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. “David is one of the most accomplished leaders in eye care, with a strong</description>
</item>
<item>
<title>Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-fourth-quarter-full-213000364</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-fourth-quarter-full-213000364</guid>
<pubDate>Tue, 17 Feb 2026 21:30:00 GMT</pubDate>
<description>IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90</description>
</item>
<item>
<title>Tarsus to Participate in Upcoming Investor Conference</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-participate-upcoming-investor-conference-2025-11-24</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-participate-upcoming-investor-conference-2025-11-24</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside</description>
</item>
<item>
<title>Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-third-quarter-2025-financial-results-and-recent-business-achievements</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-third-quarter-2025-financial-results-and-recent-business-achievements</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately</description>
</item>
<item>
<title>Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-third-quarter-2025-financial-results-tuesday-november-4-2025-2025-10-28</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-third-quarter-2025-financial-results-tuesday-november-4-2025-2025-10-28</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.</description>
</item>
<item>
<title>Tarsus to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-participate-upcoming-investor-conferences-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-participate-upcoming-investor-conferences-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the</description>
</item>
<item>
<title>Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-second-quarter-2025-financial-results-and-recent-business-achievements</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-second-quarter-2025-financial-results-and-recent-business-achievements</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer</description>
</item>
<item>
<title>Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-second-quarter-2025-financial-results-wednesday-august-6-2025-2025-07</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-second-quarter-2025-financial-results-wednesday-august-6-2025-2025-07</guid>
<pubDate>Wed, 30 Jul 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.</description>
</item>
<item>
<title>Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-first-quarter-2025-financial-results-and-recent-business-achievements</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-first-quarter-2025-financial-results-and-recent-business-achievements</guid>
<pubDate>Thu, 01 May 2025 04:00:00 GMT</pubDate>
<description>Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles</description>
</item>
<item>
<title>Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-first-quarter-2025-financial-results-thursday-may-1-2025-2025-04-24</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-first-quarter-2025-financial-results-thursday-may-1-2025-2025-04-24</guid>
<pubDate>Thu, 24 Apr 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.</description>
</item>
<item>
<title>Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-present-several-scientific-abstracts-highlighting-global-prevalence-demodex</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-present-several-scientific-abstracts-highlighting-global-prevalence-demodex</guid>
<pubDate>Tue, 22 Apr 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global</description>
</item>
<item>
<title>Tarsus Announces Pricing of Upsized $125.0 Million Public Offering</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-announces-pricing-upsized-1250-million-public-offering-2025-06-05</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-announces-pricing-upsized-1250-million-public-offering-2025-06-05</guid>
<pubDate>Wed, 12 Mar 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an</description>
</item>
<item>
<title>Tarsus Announces Proposed $100.0 Million Public Offering</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-announces-proposed-1000-million-public-offering-2025-03-12</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-announces-proposed-1000-million-public-offering-2025-03-12</guid>
<pubDate>Wed, 12 Mar 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of</description>
</item>
<item>
<title>Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-strong-fourth-quarter-and-full-year-2024-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-reports-strong-fourth-quarter-and-full-year-2024-financial-results-and-recent</guid>
<pubDate>Tue, 25 Feb 2025 05:00:00 GMT</pubDate>
<description>Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of</description>
</item>
<item>
<title>Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-fourth-quarter-and-full-year-2024-financial-results-tuesday-february-25</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-report-fourth-quarter-and-full-year-2024-financial-results-tuesday-february-25</guid>
<pubDate>Thu, 20 Feb 2025 05:00:00 GMT</pubDate>
<description>IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m.</description>
</item>
<item>
<title>Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care</title>
<link>https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-provides-2025-update-accelerating-launch-xdemvyr-and-establishing-ocular</link>
<guid isPermaLink="true">https://6ix.com/company/tarsus-pharmaceuticals-inc/news/tarsus-provides-2025-update-accelerating-launch-xdemvyr-and-establishing-ocular</guid>
<pubDate>Mon, 13 Jan 2025 05:00:00 GMT</pubDate>
<description>Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy;</description>
</item>
</channel>
</rss>